All In Biotech

Drug Trial Radar · NCT00864383

Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis

A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis

Last checked: Nov 20, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,931 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,931

Actual

Start

Jan 2008

Primary completion

Oct 2013

Study completion Feb 2014

Sponsor

Lead sponsor
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP); University College, London; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma; Sanofi
First posted
Mar 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.

Conditions

  • Pulmonary Tuberculosis

Interventions

  • Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & RifampicinDrug

    Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).Time frame: 18 months (within one year of completion of therapy)
  2. Number of Patients With Grade 3 or 4 Adverse Events (Using a Modified Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases [DAIDS] Scale of Adverse Event Reporting)Time frame: 18 months (within one year of completion of therapy)

Locations

47 sites in 9 countries. Site status is shown where the registry gives one.

  • Beijing Tuberculosis and Thoracic Tumor Research Institute

    Beijing, China

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • TB Institute

    Tianjin, China

  • A-One Hospital

    Delhi, India

  • Dr. D.K. Chauhan

    New Delhi, India

  • Centre for advanced lung and sleep disorders

    New Delhi, India

  • Dr. Mittal's clinic

    New Delhi, India

  • Diligent Hospital

    New Delhi, India

  • Ish Medical Centre and Respiratory Lab,

    New Delhi, India

  • Smt Prakash Devi Memorial Medical Centre,

    New Delhi, India

  • Nirmal Kumar Jain

    Jaipur, Rajasthan, India

  • Mahatma Gandhi Medical College& Hospital

    Jaipur, Rajsthan, India

  • Ram-Tej Hospital,

    Agra, Uttar Pradesh, India

  • Siddharth Nursing Home,

    Agra, Uttar Pradesh, India

  • Rajul Nursing Home

    Aligarh, Uttar Pradesh, India

  • Varshneya Chest Clinic & Eye Care Centre

    Aligarh, Uttar Pradesh, India

  • Dr. Neeraj Gupta Clinic

    Firozabad, Uttar Pradesh, India

  • S.P.S Chauhan Clinic

    Firozabad, Uttar Pradesh, India

  • Dr. R. K. Garg's Clinic,

    Ghaziabad, Uttar Pradesh, India

  • Indra Nursing Home and Maternity Centre

    Ghaziabad, Uttar Pradesh, India

  • Dr. AK Singh Clinic

    Kanpur, Uttar Pradesh, India

  • Dr. S. K. Katiyar, Swaroop Nagar,

    Kanpur, Uttar Pradesh, India

  • Guru Tej Bahadur Hospital

    Kanpur, Uttar Pradesh, India

  • Dr. Komal Gupta

    Lucknow, Uttar Pradesh, India

  • New City Hospital and Trauma Centre,

    Lucknow, Uttar Pradesh, India

  • Surya Chest Foundation,

    Lucknow, Uttar Pradesh, India

  • Surya Kant Clinic

    Lucknow, Uttar Pradesh, India

  • Arya Chest Clinic, UP,India

    Meerut, Uttar Pradesh, India

  • Dr. Mahip Saluja Clinic, U.P.

    Meerut, Uttar Pradesh, India

  • Dr. S. P. Sondhi Clinic,

    Meerut, Uttar Pradesh, India

  • Sri Ram Plaza

    Meerut, Uttar Pradesh, India

  • Jigyasa Medical Center

    Morādābād, Uttar Pradesh, India

  • Saanvi MultiSpeciality Clinic,

    Morādābād, Uttar Pradesh, India

  • Centre for Respiratory Disease Research at KEMRI

    Nairobi, Kenya

  • Institute of Respiratory Medicine (IPR) Jalan Pahang

    Kuala Lumpur, Malaysia

  • Hospital General de Occidente de la secretaria

    Guadalajara, Seattle, Mexico

  • Centre for TB Research and Innovation, University of Cape Town Lung Institute

    Cape Town, South Africa

  • Tiervlei Trial Center and University of Stellenbosch

    Cape Town, South Africa

  • Unit for Clinical & Biomedical TB Research, MRC Durban

    Durban, South Africa

  • Madibeng centre for Research, 40 Pienaar Street,

    Madibeng, Brits, South Africa

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.